Dr. Ingelsson obtained his MD (2000) and PhD (2005) at Uppsala University, Sweden. After internship, he did a residency in general medicine (2003-2006) and took up a postdoctoral research fellowship at the Framingham Heart Study (2006-2007). He moved to Karolinska Institutet (Stockholm, Sweden) in 2007 and was appointed Professor of Cardiovascular Epidemiology in 2010. From 2013-2016, he was a Professor of Molecular Epidemiology at Uppsala University. He was also a Visiting Professor at the Wellcome Trust Centre for Human Genetics at University of Oxford in 2012-2015. From 2016 to 2020, he was Professor of Medicine at Stanford University. During his career as a physician-scientist, Dr. Ingelsson has been doing cardiovascular research with a special focus on the role of obesity and insulin resistance in development of subclinical and clinical cardiovascular disease. His research is translational and interdisciplinary, combining big data approaches, such as -omics in population-based cohorts, with gene editing in functional model systems to reach new insights into the pathophysiology of cardiovascular disease and related conditions, identification of new biomarkers for improved risk prediction, and discovery of novel targets for drug development. Much of the focus in the past five years has been on translating human genetics findings using large-scale CRISPR gene editing methods in cell model systems. Recently, Dr. Ingelsson was appointed the Senior Vice President of Human Genetics at GlaxoSmithKline, and is now leading GSKs efforts to use human genetics as the starting point for discovery of novel drug targets for a range of diseases.